14 Feb 2018 Jahr - FDA held a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for Hydexor (proposed tradename), a fixed-dose combination oral tablet, submitted by Charleston Laboratories, Inc., that contains hydrocodone, acetaminophen, and promethazine, for the short- term management of acute pain severe enough to require an opioid analgesic while preventing and reducing opioid-induced nausea

Zugefügt zum Band der Zeit:

Opioids and the FDA

ByAnastasia

13 Nov 2018

0

0

520

Datum: